论文部分内容阅读
Objective: To assess whether the polymorphism of ERCC1 Asn118Asn (C → T) had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen for advanced colorectal cancer. Methods: ERCC1 Asn118Asn polymorphism was analyzed in 99 patients with stages III and IV advanced colorectal cancer treated with oxaliplatin-based chemotherapy. For all of the patients, ERCC1 Asn118Asn genotype was analyzed for associations with treatment response and time to disease progress (TTP). Results: The allele frequencies of the ERCC1 gene codon 118 were C/C 50.51% (50/99), C/T 41.41% (41/99), T/T 8.08% (8/99), respectively. Patients with C/C genotype showed higher response rate than those with C/T + T/T (OR = 3.764, 95% CI: 1.310-10.813). The median TTP of all patients was 7 months (95% CI: 5.569-8.431). Patients with C/C genotype showed a median TTP of 10 months (95% CI: 8.924-11.076), which was longer than 5 months (95% CI: 4.424-5.576) in patients with C/T + T/T genotypes. Conclusion: Our results showed a link between ERCC1 Asn118Asn genetic polymorphism and cancer response to oxaliplatin-based che- motherapy and time to disease progress in Chinese patients with advanced colorectal cancer. ERCC1 Asn118Asn genotyping may be of predictive benefit in selecting treatment regimen for advanced colorectal cancer.
Objective: To assess whether the polymorphism of ERCC1 Asn118Asn (C → T) had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen for advanced colorectal cancer. Methods: ERCC1 Asn118Asn polymorphism was analyzed in 99 patients with stages III and IV advanced colorectal cancer treated with oxaliplatin-based chemotherapy. For all of the patients, ERCC1 Asn118Asn genotype was analyzed for associations with treatment response and time to disease progress (TTP). Results: The allele frequencies of the ERCC1 gene Codon 118 were C / C 50.51% (50/99), C / T 41.41% (41/99), T / T 8.08% (8/99), respectively. Patients with C / C genotype showed higher response rate than those The median TTP of all patients was 7 months (95% CI: 5.569-8.431). Patients with C / C genotype showed a median (OR = 3.764, 95% CI: 1.310-10.813) TTP of 10 months (95% CI: 8.924-11.076), which was longer than 5 months (95% CI: 4.424-5. 576) in patients with C / T + T / T genotypes. Conclusion: Our results showed a link between ERCC1 Asn118Asn genetic polymorphism and cancer response to oxaliplatin-based che- motherapy and time to disease progress in Chinese patients with advanced colorectal cancer. Asn118Asn genotyping may be predictive benefit in selecting treatment regimen for advanced colorectal cancer.